IL1A and COVID-19: Current literature suggests that the use of cytokine inhibitors, such as IL-1α and IL-1β receptor antagonists, anti-IL-6 monoclonal antibodies, anti-IL-6 receptor monoclonal antibodies, anti-TNF antibodies, and Janus kinase (JAK) inhibitors, is crucial therapeutic approach in treating COVID-19 (9) (70–72).